Risankizumab
Indication
Previously treated moderately to severely active Crohn's disease (NICE TA888)
NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease
Red
Brand:
Nice TA:
888
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
1.1 Risankizumab is recommended as an option for treating moderately to severely active Crohn's disease in people 16 years and over, only if:
- the disease has not responded well enough or lost response to a previous biological treatment, or
- a previous biological treatment was not tolerated, or
- tumour necrosis factor (TNF)-alpha inhibitors are not suitable.
Risankizumab is only recommended if the company provides it according to the commercial arrangement.